OR WAIT null SECS
The companies have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States.
Moderna and Recipharm announced on Dec. 30, 2020 that they have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States.
According to a Recipharm press release, the manufacturing will take place at Recipharm’s drug product manufacturing facility in France and, subject to regulatory approval in countries outside of the US, the supply will begin in early 2021.
“We are making important progress in the development of the Moderna COVID-19 vaccine and we are pleased to be entering into this collaboration with Recipharm,” said Nicolas Chornet, senior vice-president, International Manufacturing, Moderna, in the press release. “We look forward to their support in the delivery of our vaccine to market.”
“This is a material and strategically important agreement for us, and we are delighted to be working with Moderna on such a vital project to support the long-term fight against COVID-19,” said Thomas Eldered, CEO of Recipharm, in the press release. “Our preparations are already well underway with the hiring of new staff and investment in the facility to enable us to meet the challenging timelines.”